PL3368014T3 - Nowe preparaty kannabinoidów - Google Patents

Nowe preparaty kannabinoidów

Info

Publication number
PL3368014T3
PL3368014T3 PL16798004.4T PL16798004T PL3368014T3 PL 3368014 T3 PL3368014 T3 PL 3368014T3 PL 16798004 T PL16798004 T PL 16798004T PL 3368014 T3 PL3368014 T3 PL 3368014T3
Authority
PL
Poland
Prior art keywords
new cannabinoid
cannabinoid preparations
preparations
new
cannabinoid
Prior art date
Application number
PL16798004.4T
Other languages
English (en)
Inventor
Abraham J. Domb
Amnon Hoffman
Dvora IZGELOV
Original Assignee
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd filed Critical Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd
Publication of PL3368014T3 publication Critical patent/PL3368014T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/658Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/348Cannabaceae
    • A61K36/3482Cannabis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL16798004.4T 2015-10-26 2016-10-26 Nowe preparaty kannabinoidów PL3368014T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562246224P 2015-10-26 2015-10-26
PCT/IL2016/051154 WO2017072762A1 (en) 2015-10-26 2016-10-26 Novel cannabinoid formulations

Publications (1)

Publication Number Publication Date
PL3368014T3 true PL3368014T3 (pl) 2024-03-11

Family

ID=57345998

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16798004.4T PL3368014T3 (pl) 2015-10-26 2016-10-26 Nowe preparaty kannabinoidów

Country Status (8)

Country Link
US (1) US20180325861A1 (pl)
EP (2) EP4279071A3 (pl)
AU (2) AU2016347651A1 (pl)
DK (1) DK3368014T3 (pl)
ES (1) ES2968011T3 (pl)
PL (1) PL3368014T3 (pl)
PT (1) PT3368014T (pl)
WO (1) WO2017072762A1 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2985332C (en) 2015-05-18 2023-01-03 5071, Inc. Homogenous cannabis compositions and methods of making the same
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
CA3069694A1 (en) * 2017-07-14 2019-01-17 5071, Inc. Cannabinoid compositions and methods of preparation thereof
CA3079537A1 (en) * 2017-09-02 2019-03-07 Scientific Holdings, Llc Tetrahydrocannabinol modulators
CN111225678A (zh) * 2017-10-05 2020-06-02 受体控股公司 快速起效且延长作用的植物类及合成大麻素制剂
BR112021001350A2 (pt) * 2018-07-18 2021-04-20 Glatt Gmbh formulações de liberação imediata de canabinoides
AU2019313160A1 (en) * 2018-07-31 2021-03-18 AusCann Group Holdings Ltd "solid self-emulsifying pharmaceutical compositions"
IL261132A (en) * 2018-08-13 2018-11-04 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof
CN114173797A (zh) * 2018-08-20 2022-03-11 埃克索运营公司 具有增强的大麻素谱用户体验的注入大麻的产品
AU2019325479B2 (en) * 2018-08-20 2025-07-31 Bessor Pharma, Llc Novel cannabinoids and cannabinoid acids and their derivatives
WO2020089424A1 (en) 2018-10-31 2020-05-07 Enantia, S.L. Solid compositions of cocrystals of cannabinoids
US20220008348A1 (en) * 2018-11-08 2022-01-13 Michael Golfetto Compound delivery systems and methods of production
MX2021006912A (es) * 2018-12-11 2021-08-24 Disruption Labs Inc Composiciones para la administracion de agentes terapeuticos y metodos de uso y fabricacion de las mismas.
US11458092B2 (en) 2018-12-14 2022-10-04 NuVessl, Inc. Composition with enhanced passenger molecule loading
US20200215024A1 (en) * 2019-01-08 2020-07-09 Replennabis LLC Cannabinoid formulations for treating alcohol hangover
WO2020234675A1 (en) * 2019-04-30 2020-11-26 Vialpando, Llc Amorphous cannabinoid composition and processes of manufacture
US11596606B2 (en) 2019-05-30 2023-03-07 Metta Medical Inc Activated cannabinoid controlled release compound tablet and method of forming the same
US20210169820A1 (en) 2019-09-12 2021-06-10 Nulixir Inc. Controlled release concentrate and suspensions including the same
CA3160750A1 (en) 2019-12-09 2021-06-17 Anthony Richard Gerardi Oral product comprising a cannabinoid
WO2021163023A1 (en) * 2020-02-10 2021-08-19 TRYAGx Labs Inc. Stable formulations of dronabinol
US20230210771A1 (en) * 2020-06-10 2023-07-06 Disruption Labs Inc. Compositions for the delivery of therapeutic agents and methods of use and making thereof
CN119855609A (zh) * 2022-08-12 2025-04-18 英国爵士制药研究有限公司 包含大麻素的口服固体剂型

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919113B2 (en) 1999-12-30 2011-04-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Dispersible concentrate lipospheres for delivery of active agents
EP1559423A1 (en) * 2004-02-02 2005-08-03 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Medicinal acidic cannabinoids
US20070104741A1 (en) 2005-11-07 2007-05-10 Murty Pharmaceuticals, Inc. Delivery of tetrahydrocannabinol
ES2739194T3 (es) 2012-01-19 2020-01-29 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Formulación y método para aumentar la biodisponibilidad oral de fármacos
EP3268043A4 (en) * 2015-03-10 2018-12-19 Nanosphere Health Sciences, LLC Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms

Also Published As

Publication number Publication date
ES2968011T3 (es) 2024-05-06
PT3368014T (pt) 2024-01-09
US20180325861A1 (en) 2018-11-15
WO2017072762A1 (en) 2017-05-04
EP3368014B1 (en) 2023-10-04
AU2016347651A1 (en) 2018-05-17
AU2022202259B2 (en) 2023-11-09
DK3368014T3 (da) 2024-01-08
EP3368014A1 (en) 2018-09-05
EP4279071A3 (en) 2024-01-17
AU2022202259A1 (en) 2022-04-21
CA3003120A1 (en) 2017-05-04
EP4279071A2 (en) 2023-11-22

Similar Documents

Publication Publication Date Title
IL289084A (en) Cannabinoid formulations
PL3368014T3 (pl) Nowe preparaty kannabinoidów
IL252881A0 (en) Microencapsulated cannabinoid compositions
EP3703672A4 (en) CANNABINOID FORMULATIONS
IL252550A0 (en) Transdermal cannabinoid formulations
IL254516A0 (en) Proteins specific for cd137
IL249197A0 (en) Stable cannabinoid formulations
DK3283625T3 (da) Nukleasemedieret genomeditering
EP3119391C0 (en) PROTEIN-BOUND CANNABINOID COMPOSITIONS
DK3550859T3 (da) Hovedtelefonsvirtualisering
DK3331869T3 (da) Muscarinagonister
DK3331528T3 (da) Muskarinagonister
DK3277719T3 (da) Polypeptider
EP3316375A4 (en) Redox flow cell
EP3331345A4 (en) Hedge trimmer
DK3305788T3 (da) Janus-kinase-hæmmer
DK3360890T3 (da) Genterapi
DK3331529T3 (da) Muskarinagonister
IL261341B (en) Branch instruction
DK3310450T3 (da) Olie-vand-separator
EP3290364A4 (en) Conveyor belt wear monitoring system
DK3270930T3 (da) Præeklampsi
DK3394281T3 (da) Gærcelle
EP3325857A4 (en) scraper
DK3292136T3 (da) Penicillin-g-acylaser